NASDAQ:ARIA - Ariad Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
Previous Close$23.99
Today's Range$23.99 - $23.99
52-Week Range$4.67 - $23.99
VolumeN/A
Average Volume15.70 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Ariad Pharmaceuticals (NASDAQ ARIA) News Headlines

Source:
DateHeadline
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q4 2018 Results - Earnings Call TranscriptArena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 9:09 AM
Histogen Appoints Richard Pascoe as Chairman and Chief Executive Officer - PRNewswireHistogen Appoints Richard Pascoe as Chairman and Chief Executive Officer - PRNewswire
www.prnewswire.com - January 28 at 5:43 PM
Form 8-K APRICUS BIOSCIENCES, For: Jan 23 - StreetInsider.comForm 8-K APRICUS BIOSCIENCES, For: Jan 23 - StreetInsider.com
www.streetinsider.com - January 26 at 5:15 PM
Wellington, Fidelity, State Street could emerge winners from Tesaro acquisition - Boston Business JournalWellington, Fidelity, State Street could emerge winners from Tesaro acquisition - Boston Business Journal
www.bizjournals.com - December 4 at 9:09 AM
Takeda Acquisition Of Shire May Bode Well For R&D StaffTakeda Acquisition Of Shire May Bode Well For R&D Staff
www.forbes.com - December 3 at 9:04 AM
Takeda: European Commission Approves ALUNBRIG For Patients With ALK+ NSCLC - NasdaqTakeda: European Commission Approves ALUNBRIG For Patients With ALK+ NSCLC - Nasdaq
www.nasdaq.com - November 29 at 5:04 PM
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical OfficerAnchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer
www.nasdaq.com - November 26 at 8:59 AM
Form 10-Q Deciphera Pharmaceutical For: Sep 30Form 10-Q Deciphera Pharmaceutical For: Sep 30
www.streetinsider.com - November 10 at 5:01 PM
US Biological Products (Except Diagnostic) Market Report 2018 - Analysis and Forecast 2007-2025 ...US Biological Products (Except Diagnostic) Market Report 2018 - Analysis and Forecast 2007-2025 ...
www.businesswire.com - November 10 at 5:01 PM
Cancer Research Highlight: Pfizer Looks To Re-Enter The ALK RaceCancer Research Highlight: Pfizer Looks To Re-Enter The ALK Race
seekingalpha.com - November 9 at 9:07 AM
Form 8-K INCYTE CORP For: Oct 30Form 8-K INCYTE CORP For: Oct 30
www.streetinsider.com - October 30 at 9:03 AM
Cannabis doctor found guilty in biotech insider trading caseCannabis doctor found guilty in biotech insider trading case
www.bizjournals.com - October 10 at 8:54 AM
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial OrganizationTocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
www.bizjournals.com - September 24 at 9:03 AM
(brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib(brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
www.businesswire.com - September 23 at 8:47 AM
Takeda Pharmaceutical Reports Phase 3 Trial of ALUNBRIG (brigatinib) Met Primary EndpointTakeda Pharmaceutical Reports Phase 3 Trial of ALUNBRIG (brigatinib) Met Primary Endpoint
www.streetinsider.com - July 26 at 5:03 PM
MorphoSys AG: MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global CommercialMorphoSys AG: MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial
www.finanznachrichten.de - July 25 at 8:53 AM
3 Things In Biotech, July 19: Karyopharm Rolls Out, And Cellectar Looks To Keep The Spotlight3 Things In Biotech, July 19: Karyopharm Rolls Out, And Cellectar Looks To Keep The Spotlight
seekingalpha.com - July 19 at 8:47 AM
Incyte’s Revenue Stream in 4Q17Incyte’s Revenue Stream in 4Q17
finance.yahoo.com - June 30 at 7:15 AM
Cardax Adds Makarand Jawadekar, Ph.D., and Elona Kogan to its Board of DirectorsCardax Adds Makarand Jawadekar, Ph.D., and Elona Kogan to its Board of Directors
www.prnewswire.com - June 1 at 4:51 PM
Leukemia Therapeutics Market is Determined to Cross US$ 12 Billion By 2022Leukemia Therapeutics Market is Determined to Cross US$ 12 Billion By 2022
www.marketwatch.com - May 17 at 5:18 PM
After $62 Billion Shire Win, Takeda CEO Faces More HeadachesAfter $62 Billion Shire Win, Takeda CEO Faces More Headaches
www.msn.com - May 9 at 9:08 AM
Takeda to buy Shire for $62 billionTakeda to buy Shire for $62 billion
www.bizjournals.com - May 8 at 9:02 AM
Shire (SHPG) Agrees to Be Acquired by Takeda for $62BShire (SHPG) Agrees to Be Acquired by Takeda for $62B
www.streetinsider.com - May 8 at 9:02 AM
Takeda to buy Shire for $62B, creating state’s largest drugmakerTakeda to buy Shire for $62B, creating state’s largest drugmaker
www.bizjournals.com - May 8 at 9:02 AM
Takeda Moves to Join Pharma Giants With $62 Billion Shire DealTakeda Moves to Join Pharma Giants With $62 Billion Shire Deal
www.msn.com - May 8 at 9:02 AM
Japans Takeda clinches $62 billion deal to buy drugmaker ShireJapan's Takeda clinches $62 billion deal to buy drugmaker Shire
www.reuters.com - May 8 at 9:02 AM
Cambridge’s Ironwood Pharmaceuticals to split into two businessesCambridge’s Ironwood Pharmaceuticals to split into two businesses
www.bizjournals.com - May 1 at 9:07 AM
Shire accepts a $64b takeover offer from Takeda, will seek shareholders’ backingShire accepts a $64b takeover offer from Takeda, will seek shareholders’ backing
www.msn.com - April 25 at 9:06 AM
Takeda is closing in on buying Adderall maker Shire for $64 billion in pharmas biggest deal of the yearTakeda is closing in on buying Adderall maker Shire for $64 billion in pharma's biggest deal of the year
www.businessinsider.com - April 25 at 9:06 AM
Shire bid marks Takedas latest - and biggest - push for global statusShire bid marks Takeda's latest - and biggest - push for global status
www.reuters.com - April 25 at 9:06 AM
Clarus Appoints Former Ariad CEO Paris Panayiotopoulos as Operating Partner and Member of its Investment TeamClarus Appoints Former Ariad CEO Paris Panayiotopoulos as Operating Partner and Member of its Investment Team
www.prnewswire.com - April 23 at 8:51 AM
Takeda sweetens bid for drug rival ShireTakeda sweetens bid for drug rival Shire
www.marketwatch.com - April 20 at 4:46 PM
Bidding war looms over Shire after £42.4bn Takeda offer rejectedBidding war looms over Shire after £42.4bn Takeda offer rejected
www.ft.com - April 19 at 4:56 PM
Shire rejects £42.4bn takeover bid from TakedaShire rejects £42.4bn takeover bid from Takeda
www.ft.com - April 19 at 9:02 AM
Shire Rejects Takedas $60 Billion Bid as Talks ContinueShire Rejects Takeda's $60 Billion Bid as Talks Continue
www.bloomberg.com - April 19 at 9:02 AM
Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of DirectorsTim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors
www.bizjournals.com - April 9 at 9:15 AM
Shire Would Be a Big Pill for Takeda to SwallowShire Would Be a Big Pill for Takeda to Swallow
www.wsj.com - March 30 at 4:51 PM
Takeda shares fall on possible Shire bidTakeda shares fall on possible Shire bid
www.marketwatch.com - March 29 at 9:24 AM
Takeover whispers about Shire growing much louderTakeover whispers about Shire growing much louder
www.msn.com - March 29 at 9:24 AM
Shares in £33 billion pharma giant Shire jump 25% after a possible takeover approach was announcedShares in £33 billion pharma giant Shire jump 25% after a possible takeover approach was announced
www.businessinsider.com - March 28 at 4:44 PM
Takeda eyes bid for Shire to make $90B drug giantTakeda eyes bid for Shire to make $90B drug giant
www.marketwatch.com - March 28 at 4:44 PM
Japanese pharma group Takeda weighs bid for ShireJapanese pharma group Takeda weighs bid for Shire
www.ft.com - March 28 at 4:44 PM
BioCanCell Announces Two New Key Hires in Clinical Development ... - GlobeNewswire (press release)BioCanCell Announces Two New Key Hires in Clinical Development ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 5:38 PM
Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors - GlobeNewswire (press release)Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 7 at 5:38 PM
Sarissa Capital Reconstitutes Innoviva Board Of DirectorsSarissa Capital Reconstitutes Innoviva Board Of Directors
finance.yahoo.com - February 13 at 4:12 PM
Why Innoviva Inc. Stock Jumped TuesdayWhy Innoviva Inc. Stock Jumped Tuesday
www.fool.com - February 13 at 4:12 PM
Wired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary EndpointWired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint
finance.yahoo.com - February 7 at 9:30 AM
Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice PresidentUltragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President
finance.yahoo.com - January 29 at 9:35 AM
What to watch during health-care investings biggest week of the yearWhat to watch during health-care investing's biggest week of the year
finance.yahoo.com - January 8 at 11:05 AM
US cancer drugmaker Ignyta in advanced sale talks - NasdaqUS cancer drugmaker Ignyta in advanced sale talks - Nasdaq
www.nasdaq.com - December 23 at 3:45 PM
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel